What is Rapport Therapeutics, Inc. (RAPP) stock price today?

Rapport Therapeutics, Inc. (RAPP) is currently trading at $29.77, down 0.27% today.

What is RAPP P/E ratio?

Rapport Therapeutics, Inc.'s P/E ratio is -10.38. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RAPP return on equity (ROE)?

Rapport Therapeutics, Inc.'s return on equity (ROE) is -29.02%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Rapport Therapeutics, Inc.'s market cap?

Rapport Therapeutics, Inc. has a market capitalization of $1.42B.

NASDAQ · Biotechnology

Rapport Therapeutics, Inc. (RAPP) Stock

$29.77 -0.27% NASDAQ: RAPP Healthcare

Valuation

Metric	Value
Price	$29.77
Market Cap	$1.42B
P/E Ratio	-10.38
P/B Ratio	3.54
P/S Ratio	75.43
EPS (TTM)	$-4.20
52-Week High	$52.93
52-Week Low	$23.75
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-29.02%
ROA	-29.88%
ROCE	-35.66%
Gross Margin	97.54%
Operating Margin	-6.11%
Net Margin	-685.80%
Debt/Equity	0.02
Current Ratio	26.26

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$0	$0	$0
Operating Profit	$-10.0M	$-36.0M	$-83.0M	$-125.0M
Net Profit	$-11.0M	$-35.0M	$-78.0M	$-111.0M
EPS	$-0.29	$-0.95	$-3.78	$-2.86
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$32.0M	$155.0M	$315.0M	$512.0M
Total Liabilities	$12.0M	$181.0M	$10.0M	$28.0M
Cash	$31.0M	$70.0M	$57.0M	$53.0M
Borrowings	$10.0M	$2.0M	$1.0M	$11.0M

Latest News

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? Motley Fool · Jul 12, 2026 Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target MT Newswires · Jun 24, 2026 Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? Insider Monkey · Jun 16, 2026 Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? Simply Wall St. · Jun 8, 2026 BTIG Raises its Price Target on Rapport Therapeutics (RAPP) Insider Monkey · Jun 5, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-3.0M	$-27.0M	$-65.0M	$-87.0M
Investing Cash Flow	$-6.0M	$-80.0M	$-173.0M	$-188.0M
Financing Cash Flow	$0	$0	$0	$0
Net Cash Flow	$31.0M	$39.0M	$-13.0M	$-4.0M
Free Cash Flow	$-4.0M	$-29.0M	$-67.0M	$-88.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.48
EV / EBITDA	-9.82
FCF Yield	-6.44%
Quick Ratio	15.72
Interest Coverage	0.00
Return 1Y	166.97%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held4.60%

Institutions Held109.58%

Institutions Float Held114.87%

Institutional Holder	Shares	Report Date
FMR, LLC	7,168,939	2026-03-31
Trv Gp V, LLC	7,135,233	2026-03-31
Arch Venture Management, Llc	3,728,738	2026-03-31
Capital International Investors	3,097,973	2026-03-31
Cormorant Asset Management, LP	2,957,521	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACADACADIA Pharmaceuticals Inc.	$19.82	+1.20%	8.87	$3.39B	0.00%
ANROAlto Neuroscience, Inc.	$24.42	+1.62%	-9.71	$856.99M	0.00%
AXSMAxsome Therapeutics, Inc.	$168.40	-0.99%	-49.17	$8.67B	0.00%
CGTXCognition Therapeutics, Inc.	$0.88	-1.56%	-4.82	$78.87M	0.00%
CTNMContineum Therapeutics, Inc.	$13.33	+1.10%	-7.58	$501.30M	0.00%

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. is led by CEO Abraham N. Ceesay, publicly traded since 2024.

Rapport Therapeutics, Inc. (RAPP) stock trades at $29.77 with a market capitalization of $1.42B. The stock is valued at a price-to-earnings (P/E) ratio of -10.38, price-to-book of 3.54, price-to-sales of 75.43. Over the past 52 weeks the stock has ranged between $23.75 and $52.93, and currently trades 43.8% below its 52-week high.

On profitability, Rapport Therapeutics, Inc. generates a return on equity (ROE) of -29.02%, return on capital employed of -35.66%, an operating margin of -6.11%, a net profit margin of -685.80%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.88 +0.79% JNJ Johnson & Johnson $260.66 +1.63% ABBV AbbVie Inc. $277.31 +1.80% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $151.18 +2.77% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides